Scholar Rock Holding

Update in progress

SRRK (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Scholar Rock is a Cambridge, MA biopharmaceutical company focused on rare neuromuscular diseases, including spinal muscular atrophy (SMA). It uses a proprietary platform to target latent growth factors in the TGF-β superfamily with monoclonal antibodies. Lead programs: Apitegromab, a myostatin activation inhibitor in Phase 2 for SMA and FSHD; SRK-439 in Phase 1; SRK-181 as a latent TGF-β1 inhibitor in later development; plus preclinical SRK-373 and SRK-256.

Company score

Sentiment: 0.14; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.03; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive